Plasma neuropeptides and perception of pruritus in psoriasis

Acta Dermato-Venereologica

Volumn 87, Issue 4, 2007, Pages 299-304

  Reich, Adam ^a   Orda, Alina ^a   Wiśnicka, Beata ^a   Szepietowski, Jacek C ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Calcitonin gene related peptide; Neuropeptide Y; Neuropeptides; Psoriasis; Substance P; Vasoactive intestinal peptide

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PRURITUS; PSORIASIS; RADIOIMMUNOLOGY; VISUAL ANALOG SCALE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; HOSPITALIZATION; MIDDLE AGED;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDES; PRURITUS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 34848888628     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0265     Document Type: Article

References (34)

1. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health-Syst Pharm 2000; 57: 645-659.
2. Prinz JC. Psosiaris vulgaris - a sterile antibacterial skin reaction mediated by cross reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332.
3. Farber EM, Nail L. Psoriasis: a stress-related disease. Cutis 1993; 51: 322-326.
4. Arnetz BB, Fjellner B, Eneroth P, Kallner A. Stress and psoriasis: psychoendocrine and metabolic reactions in psoriatic patients during standardized stressor exposure. Psychosom Med 1985; 47: 528-541.
5. O'Kane M, Murphy EP, Kirby B. The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease. Exp Dermatol 2006; 15: 143-153.
6. Misery L. Skin, immunity and the nervous system. Br J Dermatol 1997; 137: 843-850.
7. Raychaudhuri SP, Farber EM. Neuroimmunologic aspects of psoriasis. Cutis 2000; 66: 357-362.
8. Peters EM, Kuhlmei A, Tobin DJ, Muller-Rover S, Klapp BF, Arck PC. Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun 2005; 19: 252-262.
9. Scholzen TE, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system. Exp Dermatol 1998; 7: 81-96.
10. Yosipovitch G, Goon A, Wee J, Chan YW, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-973.
11. Szepietowski JC, Reich A, Wiśnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002; 10: 221-226.
12. Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs 2006; 18: 227-233.
13. Wiśnicka B, Szepietowski JC, Reich A, Orda A. Histamine, substance P and calcytonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis. Dermatol Psychosom 2004; 5: 73-78.
14. Reich A, Szepietowski JC, Wiśnicka B, Pacan P. Does stress influence itching in psoriatic patients? Dermatol Psychosom 2003; 4: 151-155.
15. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 49: 718-730.
16. Andoh T, Kuraishi Y. Substance P and itch. In: Yosipovitch G, Greaves MW, Fleischer Jr AB, McGlone F, editors. Itch: Basic mechanism and therapy. Marcel Dekker Inc, New York, Basel, 2004: p. 87-95.
17. Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116: 1174-1185.
18. Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999; 8: 39-45.
19. Vaalasti A, Suomalainen H, Rechardt L. Calcitonin gene-related peptide immunoreactivity in prurigo nodularis: a comparative study with neurodermatitis circumscripta. Br J Dermatol 1989; 120: 619-623.
20. Fredriksson T, Petersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-241.
21. Rifai K, Hafer C, Rosenau J, Athmann C, Haller H, Peter Manns M, Fliser D. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand J Gastroenterol. 2006; 41: 1212-1217.
22. Reich A, Orda A, Wisnicka B, Szepietowski JC. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol 2007, DOI:10.1111/j.1600-0625.2007.00544.x.
23. Saraceno R, Kleyn CE, Terenghi G, Griffiths CEM. The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155: 876-882.
24. Scholzen TE, Luger TA. Neutral endopeptidase and angiotensin-converting enzyme - key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 2004; 13, Suppl. 4: 22-26.
25. Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994; 33: 361-366.
26. Huskic J, Alendar F, Matavulj A, Ostoic L. Serum angiotensin converting enzyme in patients with psoriasis. Med Arch 2004; 58: 202-205.
27. Arnold WP, van de Kerkhof PC. Topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1994; 31: 135.
28. 2. Eur J Pharmacol 2006; 530: 281-283.
29. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23: 6176-6180.
30. Ui H, Andoh T, Lee J-B, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006; 530: 172-178.
31. Naveilhan P, Hassameh H, Lucas G, Blakeman KH, Hao J-X, Xu X-J, et al. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 2001; 409: 513-517.
32. Li JJ, Zhou X, Yu LC. Involvement of neuropeptide Y and Y1 receptor in antinociception in the arcuate nucleus of hypothalamus, an immunohistochemical and pharmacological study in intact rats and rats with inflammation. Pain 2005; 118: 232-242.
33. Smith PA, Moran TD, Abdulla F, Tumber KK, Taylor BK. Spinal mechanisms of NPY analgesia. Peptides 2007; 28: 464-474.
34. Wang J-Z. Microinjection of neuropeptide Y into periaqueductal grey produces anti-nociception in rat with mononeuropathy. Acta Physiol Sin 2004; 56: 79-82.